<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6122710</article-id><article-id pub-id-type="publisher-id">4768</article-id><article-id pub-id-type="doi">10.1186/s12885-018-4768-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Angiogenesis and radiological tumor growth in patients with glioblastoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Mikkelsen</surname><given-names>Vilde Elisabeth</given-names></name><address><phone>0047-72825263</phone><email>vildeem@stud.ntnu.no</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Stensj&#x000f8;en</surname><given-names>Anne Line</given-names></name><address><email>alinesten@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Granli</surname><given-names>Unn Sophie</given-names></name><address><email>unn.granli@ntnu.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Berntsen</surname><given-names>Erik Magnus</given-names></name><address><email>erik.berntsen@ntnu.no</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Salvesen</surname><given-names>&#x000d8;yvind</given-names></name><address><email>oyvind.salvesen@ntnu.no</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Solheim</surname><given-names>Ole</given-names></name><address><email>ole.solheim@ntnu.no</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Torp</surname><given-names>Sverre Helge</given-names></name><address><email>sverre.torp@ntnu.no</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1516 2393</institution-id><institution-id institution-id-type="GRID">grid.5947.f</institution-id><institution>Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, </institution><institution>NTNU - Norwegian University of Science and Technology, </institution></institution-wrap>Erling Skjalgssons gate 1, 7030 Trondheim, Norway </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1516 2393</institution-id><institution-id institution-id-type="GRID">grid.5947.f</institution-id><institution>Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, </institution><institution>NTNU - Norwegian University of Science and Technology, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 3560</institution-id><institution-id institution-id-type="GRID">grid.52522.32</institution-id><institution>Department of Neurosurgery, </institution><institution>St. Olavs University Hospital, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1516 2393</institution-id><institution-id institution-id-type="GRID">grid.5947.f</institution-id><institution>Cellular and Molecular Imaging Core Facility (CMIC), Faculty of Medicine and Health Sciences, </institution><institution>Norwegian University of Science and Technology (NTNU), </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 3560</institution-id><institution-id institution-id-type="GRID">grid.52522.32</institution-id><institution>Department of Radiology and Nuclear Medicine, </institution><institution>St. Olavs University Hospital, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1516 2393</institution-id><institution-id institution-id-type="GRID">grid.5947.f</institution-id><institution>Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, </institution><institution>NTNU - Norwegian University of Science and Technology, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 3560</institution-id><institution-id institution-id-type="GRID">grid.52522.32</institution-id><institution>National Advisory Unit for Ultrasound and Image Guided Therapy, </institution><institution>St. Olavs University Hospital, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1516 2393</institution-id><institution-id institution-id-type="GRID">grid.5947.f</institution-id><institution>Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, </institution><institution>NTNU - Norwegian University of Science and Technology, </institution></institution-wrap>Trondheim, Norway </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0627 3560</institution-id><institution-id institution-id-type="GRID">grid.52522.32</institution-id><institution>Department of Pathology, </institution><institution>St. Olavs University Hospital, </institution></institution-wrap>Trondheim, Norway </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>9</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>18</volume><elocation-id>862</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">The preoperative growth of human glioblastomas (GBMs) has been shown to vary among patients. In animal studies, angiogenesis has been linked to hypoxia and faster growth of GBM, however, its relation to the growth of human GBMs is sparsely studied. We have therefore aimed to look for associations between radiological speed of growth and microvessel density (MVD) counts of the endothelial markers vWF (Factor VIII&#x000a0;related antigen) and CD105&#x000a0;(endoglin).</p></sec><sec><title>Methods</title><p id="Par2">Preoperative growth was estimated from segmented tumor volumes of two preoperative T1-weighted postcontrast magnetic resonance imaging scans taken &#x02265;14&#x000a0;days apart in patients with newly diagnosed GBMs. A Gompertzian growth curve was computed from the volume data and separated the patients into two groups of either faster or slower tumor growth than expected. MVD counts of the immunohistochemical markers von Willebrand factor (vWF) (a pan-endothelial marker) and CD105 (a&#x000a0;marker of proliferating endothelial cells) were assessed for associations with fast-growing tumors using Mann-Whitney U tests and a multivariable&#x000a0;binary logistic regression analysis.</p></sec><sec><title>Results</title><p id="Par3">We found that only CD105-MVD was significantly associated with faster growth in a univariable analysis (<italic>p</italic>&#x02009;=&#x02009;0.049). However, CD105-MVD was no longer significant when corrected for the presence of thromboses and high cellular density in a multivariable model, where the latter features were significant independent predictors of faster growth with respective odds ratios 4.2 (95% confidence interval, 1.2, 14.3), <italic>p</italic>&#x02009;=&#x02009;0.021 and 2.6 (95% confidence interval, 1.0, 6.5), <italic>p</italic>&#x02009;=&#x02009;0.048.</p></sec><sec><title>Conclusions</title><p id="Par4">MVDs of neither endothelial marker were independently associated with faster growth, suggesting angiogenesis-independent processes contribute to faster glioblastoma growth.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12885-018-4768-9) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Angiogenesis</kwd><kwd>Glioblastoma</kwd><kwd>Histopathology</kwd><kwd>Magnetic resonance imaging</kwd><kwd>Microvessel density</kwd><kwd>Tumor growth</kwd><kwd>Tumor biology</kwd><kwd>Tumor hypoxia</kwd></kwd-group><funding-group><award-group><funding-source><institution>Norges Teknisk-Naturvitenskapelige Universitet (NO)</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009123</institution-id><institution>Norges Teknisk-Naturvitenskapelige Universitet</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>National Competence Centre for Ultrasound and Image Guided Therapy</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Norwegian National Advisory Unit on Functional MRI Methods </institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>Central Norwegian Brain Tumor Registry</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Glioblastoma (GBM) is the most common primary malignant brain tumor in adults [<xref ref-type="bibr" rid="CR1">1</xref>], with a median overall survival of only 10&#x000a0;months in unselected patients [<xref ref-type="bibr" rid="CR2">2</xref>]. GBMs are characterized by a highly heterogenous histopathology [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>], a high secretion of pro-angiogenic factors [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], extensive vascularity [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and rapid pretreatment growth [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. The pretreatment growth has been shown to vary considerably among patients [<xref ref-type="bibr" rid="CR10">10</xref>] and slower growth to be an independent predictor of long term survival in patients with GBM [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par22">It is of major interest to understand biological processes behind the variations in speed of growth observed in human GBMs, which in turn could reveal future targets of therapies hampering growth. We have recently studied relations between histopathological features and radiological speed of pretreatment tumor growth [<xref ref-type="bibr" rid="CR13">13</xref>]. We found that thromboses and high cellular density were significant independent predictors of faster preoperative tumor growth [<xref ref-type="bibr" rid="CR13">13</xref>]. These findings are in line with hypotheses suggesting thrombosis as an initiator of hypoxia facilitating outward tumor expansion, plausibly through stimulation of angiogenesis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Neovascularization is fundamental for the survival and expansion of tumors [<xref ref-type="bibr" rid="CR15">15</xref>], and angiogenesis has been extensively linked to hypoxia and growth of GBM in animal studies [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. However, in randomized trials, antiangiogenic therapy has not shown any significant survival benefit in GBMs [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Still, the degree of angiogenesis has not been assessed for relations with radiological speed of pretreatment growth in human GBMs.</p><p id="Par23">In a cohort of 102 GBMs previously assessed for radiological speed of growth [<xref ref-type="bibr" rid="CR10">10</xref>], we sought to investigate possible associations between pretreatment speed of tumor growth and the degree of angiogenesis quantified by microvessel density (MVD) measurements. The MVDs were immunohistochemically assessed by means of two endothelial markers: von Willebrand factor (vWF or FVIII&#x000a0;related antigen), a pan-endothelial marker [<xref ref-type="bibr" rid="CR22">22</xref>], which illustrates the metabolic demand of the tumor [<xref ref-type="bibr" rid="CR23">23</xref>]; and endoglin (CD105), a marker of proliferating endothelial cells [<xref ref-type="bibr" rid="CR24">24</xref>], which reflects the degree of angiogenesis [<xref ref-type="bibr" rid="CR23">23</xref>]. In addition, we investigated the correlation between the MVDs and their associations with the histopathological features&#x000a0;thromboses, high cellular density, high vascular density, and mitotic count.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Inclusion and exclusion criteria</title><p id="Par24">As previously described, patients were retrospectively selected from all newly diagnosed GBM patients &#x02265;18&#x000a0;years of age operated at St Olavs Hospital &#x02013; Trondheim University Hospital, Norway between January 2004 and May 2014 (262 patients) [<xref ref-type="bibr" rid="CR10">10</xref>]. Selection criteria were&#x02009;&#x02265;&#x02009;2 pretreatment T<sub>1</sub>-weighted postcontrast magnetic resonance imaging (MRI) scans separated by &#x02265;14&#x000a0;days and histopathologically verified GBMs according to the 2007 World Health Organization (WHO) Classification [<xref ref-type="bibr" rid="CR25">25</xref>]. Exclusion criteria were non-contrast-enhancing tumors and gliomatosis cerebri (defined by radiological criteria [<xref ref-type="bibr" rid="CR26">26</xref>]). In addition, four cases were excluded because of insufficient tissue amount or morphology for the MVD assessments, which left 102 patients eligible for further analyses.</p></sec><sec id="Sec4"><title>Volume segmentation and growth rates</title><p id="Par25">The segmentation of tumor volumes and establishment of growth rates have previously been described in detail [<xref ref-type="bibr" rid="CR10">10</xref>]. The volume segmentation was performed by ALS and controlled by EMB (a neuroradiologist) using the software BrainVoyager QX (Brain Innovation, Maastricht, The Netherlands). Both preoperative MRI scans were segmented for total tumor volumes, defined as the combined volume of the non-contrast-enhancing central part (i. e. necrosis) and the contrast-enhancing rim. In addition, the reproducibility of the tumor volume assessments has been assessed and concluded as satisfactory [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par26">The fitness of different growth patterns based on the segmented tumor volumes and the time intervals between the scans, have previously been assessed [<xref ref-type="bibr" rid="CR10">10</xref>]. The Gompertzian growth pattern (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) was concluded as the most biologically reasonable growth pattern [<xref ref-type="bibr" rid="CR10">10</xref>], and all tumors were assumed to follow this growth pattern. Since growth rates were highly dependent upon tumor volume [<xref ref-type="bibr" rid="CR10">10</xref>], a point estimate (such as doubling time) would be a wrong representation of tumor growth. To account for this issue, we calculated an expected Gompertzian growth curve based on the volume data from 106 patients [<xref ref-type="bibr" rid="CR10">10</xref>]. The curve dichotomized the patients into having tumors with a larger or smaller volume increase than expected from the curve (i.e. fast-growing or slow-growing tumors) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR10">10</xref>]. These two groups have previously been shown to associate with survival of GBM patients [<xref ref-type="bibr" rid="CR12">12</xref>]. In the current study, these groups were assessed for associations with the MVDs.<fig id="Fig1"><label>Fig. 1</label><caption><p>Gompertzian growth pattern. The expected Gompertzian growth curve computed from segmented tumor volumes of two preoperative MRI scans and the interval between them in 106 patients [<xref ref-type="bibr" rid="CR10">10</xref>]. Time is presented as a logarithmic scale. The squares represent tumor volumes at the second MRI scans: the black squares are tumor volumes with a larger increase in size than expected from their initial volume (fast-growing tumors), while the red squares are tumors with a smaller volume increase than expected from the curve (slow-growing tumors). For illustration purposes, the curve was drawn from a tumor with an arbitrary size of 0.135&#x000a0;mL at day 0</p></caption><graphic xlink:href="12885_2018_4768_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec5"><title>Histopathology</title><p id="Par27">All routine hematoxylin-eosin (HE) sections for each case have previously been microscopically assessed by VEM (a medical research student) and controlled by SHT (an experienced neuropathologist) for the presence of 30 different histopathological features, which have previously been described in detail [<xref ref-type="bibr" rid="CR13">13</xref>]. These features were assessed for associations with the same groups of growth, and thromboses, high cellular density, vascular density, and mitotic count were of interest to this study. Thromboses were defined as vascular structures partly or completely occluded with fibrin. The general cellular and vascular densities of viable tumor areas were subjectively graded as low, moderate, or high. For statistical analyses, the 2 lowest categories were merged, because very few cases were graded as low in both variables. Mitoses were counted in 10 high-power fields (HPFs) in areas of highest mitotic counts (hotspots).</p></sec><sec id="Sec6"><title>Immunohistochemistry</title><p id="Par28">From each patient, one representative tumor sample from formalin-fixed paraffin-embedded (FFPE) tissue were cut at 4&#x000a0;&#x003bc;m, dried, deparaffinized, and rehydrated. Of the 102 cases, 11 cases had sections from FFPE frozen tissue. We applied vWF (vWF, 1:2000, polyclonal rabbit, EnV+/HRP, Dako Denmark AS, Glostrup, Denmark) and CD105 (CD105, SN6h, 1:50, monoclonal mouse, LSAB/HRP, Dako Denmark AS, Glostrup, Denmark). Optimum antibody concentrations were determined by titrations. For CD105, antigen retrieval was achieved with proteolytic enzymes, endogenous peroxidase activity was quenched with peroxidase block, and sections were incubated with the primary antibody for 24&#x000a0;h at 4&#x000a0;&#x000b0;C with cover glass after pretreatment with serumfree proteinblock. Both endothelial markers had negative controls and positive internal controls.</p></sec><sec id="Sec7"><title>Quantification of microvessel densities</title><p id="Par29">MVDs of vWF and CD105 were assessed by VEM, who was blinded to the growth data. A Nikon Eclipse 80i microscope and a Nikon CFI 10&#x000d7;/22 grid at&#x000a0;&#x000d7; 400 magnification (area within the grid equal to 0.059&#x000a0;mm<sup>2</sup>) were used for the MVD assessments. MVDs were assessed after the methods of Weider et al. [<xref ref-type="bibr" rid="CR27">27</xref>] with some modifications. MVDs were computed as the mean count of vessels within the grid for three HPFs of highest vascular densities (i. e. hotspots). Hotspots were identified by scanning using &#x000d7;&#x02009;4 and &#x000d7;&#x02009;10 objectives on vWF sections; corresponding hotspots were identified on CD105 sections. Only areas with &#x02265;50% of viable central tumor tissue were counted. Tissue edges and areas with excessive hemorrhage and/or desmoplasia were avoided. Any individually stained endothelial cell or vessel within or in contact with the grid were counted. Moreover, because of the heterogeneous morphology of GBM vessels [<xref ref-type="bibr" rid="CR28">28</xref>], each lumen was counted for long branched vessels and glomeruloid tufts as described by Kraby et al. [<xref ref-type="bibr" rid="CR29">29</xref>]. In addition, separate units of &#x02265;2 staining endothelial cells within the same vascular structure were counted as one vascular unit. Altogether, one case was not assessed for vWF-MVD due to high background staining, and another case was not evaluated for CD105-MVD due to non-existent antigenicity.</p></sec><sec id="Sec8"><title>Statistical analyses</title><p id="Par30">The estimation of growth rates and curves were computed using R version 2.13.1 [<xref ref-type="bibr" rid="CR10">10</xref>] and analyses involving histopathology and MVDs were performed using IBM SPSS Statistics 24. Statistical significance was defined as <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 without corrections for multiple testing. The correlation between vWF-MVD and CD105-MVD was assessed using the Spearman rank correlation test. Associations between both MVDs and histopathological features were assessed using Mann-Whitney U tests (categorical vs continuous) and Spearman rank correlation tests (continuous vs continuous). vWF-MVD and CD105-MVD were further investigated for associations with fast-growing tumors using Mann-Whitney U tests. Finally, CD105-MVD was included in a multivariable binary logistic regression model with the histopathological features previously found to be significantly associated with faster growth in the same patients (thromboses, high cellular density, and mitotic count) [<xref ref-type="bibr" rid="CR13">13</xref>]. Mitotic count was excluded from the model due to significant associations with all other features included [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Patient characteristics</title><p id="Par31">Of the 102 included patients, 69% (70 patients) were male. The mean age was 63&#x000a0;years, range 26&#x02013;83&#x000a0;years old. All cases were immunopositive for glial fibrillary acidic protein (GFAP) and two for isocitrate dehydrogenase mutation (IDH1-R132H) [<xref ref-type="bibr" rid="CR12">12</xref>]. Eighty-two patients (80%) were preoperatively treated with corticosteroids. The median tumor volume was 17.7&#x000a0;mL (range 0.05&#x02013;146.45&#x000a0;mL) from the first MRI scans and 27.5&#x000a0;mL (range 0.98&#x02013;243.52&#x000a0;mL) from the second MRI scans. The median interval between the scans was 22.5&#x000a0;days, range 14&#x02013;98&#x000a0;days. Overall, 52 patients (51%) had fast-growing tumors, and patient characteristics within the growth groups have previously been reported [<xref ref-type="bibr" rid="CR12">12</xref>].</p></sec><sec id="Sec11"><title>Descriptive data</title><p id="Par32">We observed that both markers stained endothelial cells quite specifically. vWF had a strong and granular cytoplasmic staining pattern, whereas CD105 had a more even and occasionally weaker cytoplasmic stain (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Generally, little background staining was observed, except in a few vWF sections. The distributions of both vWF-MVD and CD105-MVD were skewed, and the median vWF-MVD was 15.5 per field (range 0.7&#x02013;62.0) and the median CD105-MVD was 12.7 (range 0.7&#x02013;50.0).<fig id="Fig2"><label>Fig. 2</label><caption><p>Vascular structures at HE, vWF, and CD105 stains. Pictures are taken from corresponding HPFs in the same tumor of an area of high vascular density at &#x000d7;&#x02009;400 magnification. <bold>a</bold> HE stain. Plenty of visible small vascular structures in an area of central tumor with small cell morphology. <bold>b</bold> vWF stain. Granular cytoplasmic staining. <bold>c</bold> CD105 stain. More even cytoplasmic staining</p></caption><graphic xlink:href="12885_2018_4768_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec12"><title>Relationships between MVDs of the endothelial markers</title><p id="Par33">vWF-MVDs and CD105-MVDs were significantly correlated (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, &#x003c1;&#x02009;=&#x02009;0.92). A scatterplot showing the relationship is found in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The median CD105-MVD/vWF-MVD ratio was 0.91 with 95% confidence interval (0.87, 0.95).<fig id="Fig3"><label>Fig. 3</label><caption><p>Scatterplot of vWF-MVD and CD105-MVD. The scatterplot shows the close correlation between the markers, with dots forming a close-to linear pattern in line with the high correlation coefficient (&#x003c1;&#x02009;=&#x02009;0.92). However, the spread increases for higher MVD counts</p></caption><graphic xlink:href="12885_2018_4768_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec13"><title>MVD and histopathology</title><p id="Par34">Of the features previously found to significantly associate with faster growth in univariable analyses (thromboses, high cellular density, and mitotic count) [<xref ref-type="bibr" rid="CR13">13</xref>], only mitotic count was significantly associated with any MVD in this study (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). However, CD105-MVD tended to be higher in cases with present thromboses or high cellular density despite the non-significant associations. The same tendency was observed for vWF-MVD and thromboses (Table <xref rid="Tab1" ref-type="table">1</xref>). Interestingly, both MVDs were significantly associated with subjectively evaluated high vascular densities on HE sections.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Associations between MVDs and histopathological features</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Histopathological features<sup>a</sup></th><th>vWF-MVD<break/>(Median, 95% CI, &#x003c1;)</th><th>CD105-MVD<break/>(Median, 95% CI,&#x000a0;&#x003c1;)</th></tr></thead><tbody><tr><td>Thromboses</td><td><italic>p</italic>&#x02009;=&#x02009;0.160</td><td><italic>p</italic>&#x02009;=&#x02009;0.125</td></tr><tr><td>&#x02003;- Not present</td><td>12.0 (8.0, 21.8)</td><td>9.3 (7.2, 17.2)</td></tr><tr><td>&#x02003;- Present</td><td>15.7 (15.5, 20.2)</td><td>13.3 (13.9, 18.4)</td></tr><tr><td>High cellular density</td><td><italic>p</italic>&#x02009;=&#x02009;0.345</td><td><italic>p</italic>&#x02009;=&#x02009;0.082</td></tr><tr><td>&#x02003;- Not present</td><td>14.7 (14.0, 19.3)</td><td>12.0 (12.1, 16.8)</td></tr><tr><td>&#x02003;- Present</td><td>17.3 (14.6, 23.2)</td><td>16.3 (13.9, 21.9)</td></tr><tr><td rowspan="2">Mitotic count<sup>b</sup></td><td><italic>p</italic>&#x02009;=&#x02009;0.004*</td><td><italic>p</italic>&#x02009;=&#x02009;0.001*</td></tr><tr><td>&#x003c1;&#x02009;=&#x02009;0.29</td><td>&#x003c1;&#x02009;=&#x02009;0.33</td></tr><tr><td>High vascular density</td><td><italic>p</italic>&#x02009;=&#x02009;0.016*</td><td><italic>p</italic>&#x02009;=&#x02009;0.004*</td></tr><tr><td>&#x02003;- Not present</td><td>13.5 (12.9, 18.5)</td><td>11.3 (11.3, 15.8)</td></tr><tr><td>&#x02003;- Present</td><td>17.5 (16.5, 24.0)</td><td>16.5 (15.2, 22.9)</td></tr></tbody></table><table-wrap-foot><p><italic>vWF-MVD</italic> Microvessel density count of von Willebrand factor. <italic>CD105-MVD</italic> Microvessel density count of CD105. <italic>CI</italic> Confidence interval. <italic>p</italic>: <italic>p</italic>-value. <italic>&#x003c1;</italic> Spearman correlation coefficient. <sup>a</sup> Subjectively assessed on hematoxylin-eosin sections. <sup>b</sup> Counted in hotspots for 10 high-power fields. *Statistically significant associations, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec14"><title>MVD and growth</title><p id="Par35">In this study, only CD105-MVD was significantly associated with faster tumor growth in the univariable analyses (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). However, the ranges of both MVDs were quite wide within both fast and slow-growing tumors (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). Nevertheless, CD105-MVD was no longer significant in a multivariable model including thromboses and high cellular density, where the two latter features were significant independent predictors of faster growth (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Univariable analyses of associations between MVDs and tumor growth, Mann-Whitney U tests</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Slow-growing tumors</th><th>Fast-growing tumors</th><th><italic>p</italic>-values</th></tr></thead><tbody><tr><td rowspan="3">vWF-MVD</td><td>Median: 13.7 95% CI (12.9, 18.2)</td><td>Median: 17.3 95% CI (15.5, 22.7)</td><td rowspan="3"><italic>p</italic>&#x02009;=&#x02009;0.211</td></tr><tr><td>Range: 2.7&#x02013;44.7</td><td>Range: 0.7&#x02013;62.0</td></tr><tr><td><italic>N</italic>&#x02009;=&#x02009;49</td><td><italic>N</italic>&#x02009;=&#x02009;52</td></tr><tr><td rowspan="3">CD105-MVD</td><td>Median: 11.7 95% CI (11.0, 16.2)</td><td>Median: 16.3 95% CI (14.2, 20.5)</td><td rowspan="3"><italic>p</italic>&#x02009;=&#x02009;0.049*</td></tr><tr><td>Range: 1.0&#x02013;42.7</td><td>Range: 0.7&#x02013;50.0</td></tr><tr><td><italic>N</italic>&#x02009;=&#x02009;50<sup>a</sup></td><td><italic>N</italic>&#x02009;=&#x02009;51<sup>a</sup></td></tr></tbody></table><table-wrap-foot><p><italic>vWF-MVD</italic> Microvessel density count of von Willebrand factor. <italic>CD105-MVD</italic> Microvessel density count of CD105. <italic>CI</italic> Confidence interval. <italic>N</italic> Number of cases. * Statistically significant associations, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05. <sup>a</sup> One case was excluded from the vWF-MVD assessment, and another from the CD105-MVD assessment. These two cases were in different growth groups, which caused the change in number of cases for each group</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig. 4</label><caption><p>Boxplots of vWF-MVD and CD105-MVD in slow and fast-growing tumors. Both MVDs show tendencies towards higher counts in fast-growing tumors, however, the spreads are large within both growth groups</p></caption><graphic xlink:href="12885_2018_4768_Fig4_HTML" id="MO4"/></fig><table-wrap id="Tab3"><label>Table 3</label><caption><p>Multivariable binary logistic regression analysis of morphologic features and faster growth</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Morphological features</th><th>Multivariable odds ratio (95% CI)</th><th>Multivariable <italic>p</italic>-values</th></tr></thead><tbody><tr><td>High cellular density<sup>a</sup></td><td>2.55 (1.007, 6.475)</td><td>0.048*</td></tr><tr><td>Thromboses<sup>a</sup></td><td>4.21 (1.245, 14.253)</td><td>0.021*</td></tr><tr><td>CD105-MVD</td><td>1.03 (0.982, 1.070)</td><td>0.255</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> Confidence interval. <italic>CD105-MVD</italic> Microvessel density count of CD105. <sup>a</sup>Subjectively assessed on hematoxylin-eosin sections. *Statistically significant associations, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par36">In this study, CD105-MVD, and not vWF-MVD, was significantly associated with faster growth in the univariable analyses. However, the relation was lost when adjusted for the presence of thromboses and high cellular density in a multivariable model, where these two latter features were significant independent predictors of faster growth. Both MVDs associated significantly with mitotic count, but neither with the presence of thromboses nor high cellular density.</p><p id="Par37">Biological reasons for why some GBMs grow faster than others are sparsely studied in human patients, which is mainly due to difficulties in acquiring in vivo pretreatment growth estimates [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In addition, most research on growth processes have been conducted on in vitro or animal models which fail to accurately imitate the unique micro-milieu of the human GBM [<xref ref-type="bibr" rid="CR30">30</xref>]. Moreover, by having preoperative growth as an outcome variable instead of overall survival, we avoid the effects of clinical factors found to be influential on survival, such as age at diagnosis, tumor size at diagnosis, Karnofsky performance status, comorbidity, and effects of treatment. Corticosteroid treatment was the only preoperative treatment received by our patients (82 patients); however, it was not significantly associated with tumor growth when corrected for tumor volume [<xref ref-type="bibr" rid="CR10">10</xref>], and associations between histopathology and growth were independent of such treatment [<xref ref-type="bibr" rid="CR13">13</xref>]. Altogether, these aspects of the study made it possible to study the biology of GBM growth as unaffected as clinically justifiable.</p><sec id="Sec16"><title>Endothelial markers and angiogenesis</title><p id="Par38">The prognostic role of MVD measurements in glioblastomas is unclarified [<xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>]. However, a few studies have reported that vWF-MVD and CD105-MVD may predict the malignancy grade and prognosis of gliomas [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. The finding that only CD105-MVD was significantly associated with growth in the univariable analyses, is in line with other univariable studies which have found more promising results for CD105-MVD than for CD31-MVD (a pan-endothelial marker) as prognostic markers of GBM [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. These studies speculated the potential prognostic inferiority of pan-endothelial markers (i.e vWF, CD31, CD34) was caused by the additional staining of pre-existing angiogenically inactive vessels [<xref ref-type="bibr" rid="CR23">23</xref>]. In contrast, many studies have shown that CD105 predominantly stain proliferating endothelial cells [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR46">46</xref>]. However, a few studies have observed CD105-positive vessels in normal [<xref ref-type="bibr" rid="CR47">47</xref>] and GBM-adjacent brain tissue [<xref ref-type="bibr" rid="CR48">48</xref>], and the marker needs further validation. Moreover, it has been shown that vWF sometimes fail to stain microvessels in both normal and neoplastic tissue [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par39">vWF-MVD and CD105-MVD were highly correlated (Fig. <xref rid="Fig3" ref-type="fig">3</xref>), with a higher median and upper range for vWF-MVD. In addition, the high CD105-MVD/vWF-MVD ratio suggests most vasculature of GBM are angiogenically active. Because the markers were counted in corresponding HPFs, a high correlation coefficient was expected. However, some of the differences in the MVDs could be caused by random variations in vascular densities of different sections and the granular staining of vWF (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), which sometimes made it more difficult to distinguish separate vascular units than in CD105&#x000a0;sections.</p></sec><sec id="Sec17"><title>Neovasculature and tumor growth</title><p id="Par40">CD105-MVD was no longer significantly associated with preoperative tumor growth in a multivariable model with thromboses and high cellular density, where both latter features were significant independent predictors of faster growth (Table <xref rid="Tab3" ref-type="table">3</xref>). However, reverse causation may also be possible: faster growth could lead to thromboses and high cellular density. Furthermore, we observed that fast-growing tumors could have quite low CD105-MVD scores and slow-growing quite high (Table <xref rid="Tab2" ref-type="table">2</xref>, Fig. <xref rid="Fig4" ref-type="fig">4</xref>), which was in line with the finding that CD105-MVD explained very little of the variance in speed of growth (3%) in the univariable analysis (data not shown). Similar ranges of CD105-MVD were observed within the growth groups when patients with sparse tissue amounts (46 cases) were excluded (Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>), and the weak association was thus unlikely a result of sampling errors. Altogether, our results suggest that vWF-MVD and CD105-MVD are not predictive of faster GBM growth.</p><p id="Par41">There are several biological mechanisms which could potentially explain the inferiority of CD105-MVD as an independent predictor of tumor growth. One reason could be that tumors can create a surplus of or ineffective vasculature due to excessive angiogenic stimuli [<xref ref-type="bibr" rid="CR23">23</xref>], potentially leading to an overrepresentation of MVD counts. Excessive angiogenic stimuli may be caused by oncogenic mutations (known as hypoxia-independent angiogenesis [<xref ref-type="bibr" rid="CR49">49</xref>]). Other explanations could be that other mechanisms of glioma-associated neovascularization account for additionally needed vasculature in fast-growing tumors [<xref ref-type="bibr" rid="CR49">49</xref>], such as vascular co-option [<xref ref-type="bibr" rid="CR50">50</xref>], vasculogenesis [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>], vascular mimicry (non-endothelial vasculature) [<xref ref-type="bibr" rid="CR53">53</xref>], and glioblastoma-endothelial cell transdifferentiation [<xref ref-type="bibr" rid="CR42">42</xref>]. Vascular mimicry is the process most likely to be overlooked by our methodology due to the lack of endothelial cells. In addition, the presence of vascular mimicry has been found to significantly predict higher glioma grades and worse prognosis [<xref ref-type="bibr" rid="CR53">53</xref>]. However, it is uncertain to which degree and how the different processes of neovascularization interact, and further studies are needed [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par42">In our previous study, we speculated that hypoxia initiated by thromboses facilitated growth through an induction of angiogenesis [<xref ref-type="bibr" rid="CR13">13</xref>]. However, the finding that the presence of thromboses was still a significant independent predictor of faster tumor growth when the degree of angiogenesis was not, suggests angiogenesis-independent mechanisms driven by hypoxia contribute to faster GBM growth. Such hypoxia induced mechanisms may act through other mechanisms of glioma-associated vascularization [<xref ref-type="bibr" rid="CR49">49</xref>], augmentation of proliferation [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>], and initiation of invasiveness [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. Increased invasiveness is one of the proposed mechanisms of resistance to anti-VEGF (bevacizumab) treatment [<xref ref-type="bibr" rid="CR55">55</xref>&#x02013;<xref ref-type="bibr" rid="CR59">59</xref>], and thus the lack of survival benefit in randomized trials [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Some studies even suggest GBM growth is possible without an induction of angiogenesis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Such angiogenesis-independent growth may be described by the &#x0201c;go-or-grow&#x0201d; hypothesis, where tumor cells switch between two mutually exclusive phenotypes of either proliferative or invasive characteristics [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. Hypoxia has been proposed to induce the switch to the invasive phenotype [<xref ref-type="bibr" rid="CR62">62</xref>]. In this way, hypoxic tumor cells migrate away from hypoxic areas and switch back to a proliferative phenotype when nutrients are adequate without an induction of angiogenesis [<xref ref-type="bibr" rid="CR60">60</xref>]. In addition, Sakariassen et al. [<xref ref-type="bibr" rid="CR19">19</xref>], discovered that xenotransplanted GBMs in nude rats could present as fatal diseases without signs of angiogenesis. Nevertheless, invading cells are unlikely to be captured as contrast enhancement without an induction of angiogenesis [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR63">63</xref>], and are therefore unlikely to have been measured in our study. Additionally, the non-significant multivariable association for CD105-MVD could perhaps be caused by the nearly significant associations between CD105-MVD and thromboses and high cellularity (Table <xref rid="Tab1" ref-type="table">1</xref>). Collectively, our findings support that angiogenesis-independent mechanisms driven by hypoxia contribute to faster GBM growth, which might explain the lack of survival benefit of anti-VEGF treatment.</p><p id="Par43">As thromboses, high cellular density maintained its role as a significant independent predictor of faster growth in our study (Table <xref rid="Tab3" ref-type="table">3</xref>). This finding substantiates our previous speculation that it is a better marker of high proliferation rates than high mitotic counts, because mitotic count has many potential sources of errors [<xref ref-type="bibr" rid="CR64">64</xref>], and higher counts were significantly associated with the presence of thromboses [<xref ref-type="bibr" rid="CR13">13</xref>] and increasing CD105-MVD counts (Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec18"><title>Microvessel methodology</title><p id="Par44">So far, there is no standard method for quantification of MVD, however, initiatives on international standardizations have been made [<xref ref-type="bibr" rid="CR65">65</xref>]. Like in our study, most studies are based on the&#x000a0;methods described&#x000a0;by Weidner et al. [<xref ref-type="bibr" rid="CR27">27</xref>] with modifications: they count single positive cells and avoid areas of sclerosis, necrosis, and non-neoplastic tissue. However, few have specified their handling of glumeruloid tufts and longer vessels. We believe as Leon et al. [<xref ref-type="bibr" rid="CR36">36</xref>], that counting a glomeruloid tuft as one vascular unit might underestimate the angiogenic stimuli of the tumor. Furthermore, the subjective assessment of hotspots and interpretation of positive immunostaining give rise to problematic inter-observer variability, which has been reported as quite high for MVD assessments in GBMs [<xref ref-type="bibr" rid="CR66">66</xref>].</p><p id="Par45">Even though we found significant associations with both MVDs and subjectively assessed high vascular densities on HE slides, the spreads of the&#x000a0;MVDs were wide within&#x000a0;and overlapping between the categories of vascular density (Table <xref rid="Tab1" ref-type="table">1</xref>). These findings were in line with the fact that capillaries is known to be inconspicuous on HE slides [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec19"><title>Strengths and limitations</title><p id="Par46">Limitations of the assessments of tumor volumes on MRI scans, growth rates, and histopathological features have previously&#x000a0;been described in detail [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. The main strengths are the relatively large number of patients with a population based referral and the reproducibility assessment of tumor volumes [<xref ref-type="bibr" rid="CR10">10</xref>]. Potential biases are selection biases, preoperative steroid treatment, differences in diagnostic MRI scanners, different timing and administration of the contrast agent, tumor cells existing beyond the contrast enhancing rim [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>], and sampling errors and inter-observer variability of the histopathological assessments. Additionally, our analyses were exploratory and should be validated in future studies.</p></sec></sec><sec id="Sec20"><title>Conclusions</title><p id="Par47">Our results showed that MVD assessments of vWF and CD105 were not independent predictors of radiological&#x000a0;speed of growth, although CD105-MVD was significantly associated with faster growth in the univariable analysis. In contrast, thromboses and high cellular density were significant independent predictors of faster growth. In summary, our findings suggest angiogenesis-independent mechanisms contribute to faster GBM growth.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec21"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2018_4768_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>Univariable analysis of associations between CD105-MVD and tumor growth when cases with sparse tissue amount are excluded (46 cases). Mann-Whitney U tests. CD105-MVD: Microvessel density count of CD105. CI: Confidence interval. N: Number of cases. (DOCX 12 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12885_2018_4768_MOESM2_ESM.xlsx"><label>Additional file 2:</label><caption><p>Dataset supporting conclusions. The minimal dataset necessary to replicate the findings reported in the article. Microvessel densities (MVDs) of both markers are presented as mean counts for 3 high-power fields (HPFs). Regarding the categorical histopathological features (thromboses, high cellular density, and high vascular density), &#x0201c;1&#x0201d; indicates that features are present, while &#x0201c;0&#x0201d; indicates that they are not. Mitotic counts are counted in 10 HPFs. Tumors growing faster than expected are indicated by &#x0201c;1&#x0201d;, whereas slow-growing tumors are indicated by &#x0201c;0&#x0201d;. Patients preoperatively treated with corticosteroids or having sparse amount of tissue available for the histopathological evaluation are indicated by &#x0201c;1&#x0201d; in the respective variables. (XLSX 15 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>CD</term><def><p id="Par5">Clusters of differentiation</p></def></def-item><def-item><term>FFPE</term><def><p id="Par6">Formalin-fixed paraffin-embedded</p></def></def-item><def-item><term>GBM</term><def><p id="Par7">Glioblastoma</p></def></def-item><def-item><term>GFAP</term><def><p id="Par8">Glial fibrillary acidic protein</p></def></def-item><def-item><term>HE</term><def><p id="Par9">Hematoxylin-eosin</p></def></def-item><def-item><term>HPF</term><def><p id="Par11">High-power field</p></def></def-item><def-item><term>HRP</term><def><p id="Par12">Horseradish peroxidase</p></def></def-item><def-item><term>IDH1</term><def><p id="Par13">Isocitrate dehydrogenase 1</p></def></def-item><def-item><term>LSAB</term><def><p id="Par14">Labeled streptavidin-biotin</p></def></def-item><def-item><term>MRI</term><def><p id="Par15">Magnetic resonance imaging</p></def></def-item><def-item><term>MVD</term><def><p id="Par16">Microvessel density</p></def></def-item><def-item><term>OR</term><def><p id="Par17">Odds ratio</p></def></def-item><def-item><term>VEGF</term><def><p id="Par18">Vascular endothelial growth factor</p></def></def-item><def-item><term>vWF</term><def><p id="Par19">von Willebrand factor</p></def></def-item><def-item><term>WHO</term><def><p id="Par20">World Health Organization</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We thank the staff at the Cellular and Molecular Imaging Core Facility (CMIC) for excellent laboratory work.</p><sec id="FPar1"><title>Funding</title><p id="Par48">VEM and ALS received research scholarship from the Norwegian University of Science and Technology (NTNU). OS received research salaries from the National Competence Centre for Ultrasound and Image Guided Therapy. EMB received research funding from the Norwegian National Advisory Unit on Functional MRI Methods and the Central Norwegian Brain Tumor Registry. The funding sources had no role in the design of the study, and collection, analysis, and interpretation of the data, or writing of the manuscript.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par49">The dataset supporting the conclusions of this article are included in its additional files (see Additional&#x000a0;file&#x000a0;<xref rid="MOESM2" ref-type="media">2</xref>).</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>VEM and SHT conceived and designed the study. VEM and SHT confirmed the histopathological diagnoses and performed the assessment of histopathological features. VEM did the microvessel density assessments. USG performed the immunohistochemical staining of vWF and CD105. ALS and EMB performed the segmentations of tumor volumes on MRI scans. ALS and &#x000d8;S computed the growth data. VEM, ALS, &#x000d8;S, OS, and SHT were involved in the analysis and interpretation of data. VEM wrote the manuscript, and all authors have critically revised the manuscript. The study was supervised by OS and SHT. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p>The study was approved by the Regional Ethics Committee (Central) as part of a larger project (references 2011/974 and 2013/1348) and adhered with the Declaration of Helsinki. Most patients had provided written informed consent to be included in a related glioma outcome study (reference 2011/974). The regional ethics committee waived informed consent for retrospective evaluation of patient data for the remaining patients, and did not require obtained written informed consent from a relative/guardian.</p></sec><sec id="FPar4"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p>O.S. has previously been an unpaid member of a national advisory committee on treatment guidelines for brain tumors. All other authors disclose no potential conflicts of interest.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><name><surname>Gittleman</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kromer</surname><given-names>C</given-names></name><name><surname>Wolinsky</surname><given-names>Y</given-names></name><name><surname>Kruchko</surname><given-names>C</given-names></name><etal/></person-group><article-title>CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013</article-title><source>Neuro-Oncology</source><year>2016</year><volume>18</volume><fpage>v1</fpage><lpage>v75</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now207</pub-id><?supplied-pmid 28475809?><pub-id pub-id-type="pmid">28475809</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ronning</surname><given-names>PA</given-names></name><name><surname>Helseth</surname><given-names>E</given-names></name><name><surname>Meling</surname><given-names>TR</given-names></name><name><surname>Johannesen</surname><given-names>TB</given-names></name></person-group><article-title>A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme</article-title><source>Neuro-Oncology</source><year>2012</year><volume>14</volume><fpage>1178</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos153</pub-id><?supplied-pmid 22869622?><pub-id pub-id-type="pmid">22869622</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burger</surname><given-names>PC</given-names></name><name><surname>Kleihues</surname><given-names>P</given-names></name></person-group><article-title>Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies</article-title><source>Cancer</source><year>1989</year><volume>63</volume><fpage>2014</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19890515)63:10&#x0003c;2014::AID-CNCR2820631025&#x0003e;3.0.CO;2-L</pub-id><?supplied-pmid 2539242?><pub-id pub-id-type="pmid">2539242</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eder</surname><given-names>K</given-names></name><name><surname>Kalman</surname><given-names>B</given-names></name></person-group><article-title>Molecular heterogeneity of glioblastoma and its clinical relevance</article-title><source>Pathol Oncol Res</source><year>2014</year><volume>20</volume><fpage>777</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1007/s12253-014-9833-3</pub-id><?supplied-pmid 25156108?><pub-id pub-id-type="pmid">25156108</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>CR</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name></person-group><article-title>Glioblastoma</article-title><source>Arch Pathol Lab Med</source><year>2007</year><volume>131</volume><fpage>397</fpage><lpage>406</lpage><?supplied-pmid 17516742?><pub-id pub-id-type="pmid">17516742</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaur</surname><given-names>B</given-names></name><name><surname>Khwaja</surname><given-names>FW</given-names></name><name><surname>Severson</surname><given-names>EA</given-names></name><name><surname>Matheny</surname><given-names>SL</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name></person-group><article-title>Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis</article-title><source>Neuro-Oncology</source><year>2005</year><volume>7</volume><fpage>134</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1215/S1152851704001115</pub-id><?supplied-pmid 15831232?><pub-id pub-id-type="pmid">15831232</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>I</given-names></name><name><surname>Gagner</surname><given-names>JP</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Newcomb</surname><given-names>EW</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name></person-group><article-title>Angiogenesis in gliomas: biology and molecular pathophysiology</article-title><source>Brain Pathol</source><year>2005</year><volume>15</volume><fpage>297</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2005.tb00115.x</pub-id><?supplied-pmid 16389942?><pub-id pub-id-type="pmid">16389942</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname><given-names>M</given-names></name><name><surname>Kurozumi</surname><given-names>K</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Date</surname><given-names>I</given-names></name></person-group><article-title>Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme</article-title><source>Neurol Med Chir (Tokyo)</source><year>2013</year><volume>53</volume><fpage>755</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.2176/nmc.ra2013-0200</pub-id><pub-id pub-id-type="pmid">24162241</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brat</surname><given-names>DJ</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name></person-group><article-title>Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma</article-title><source>Lab Investig</source><year>2004</year><volume>84</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/labinvest.3700070</pub-id><?supplied-pmid 14990981?><pub-id pub-id-type="pmid">14990981</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensjoen</surname><given-names>AL</given-names></name><name><surname>Solheim</surname><given-names>O</given-names></name><name><surname>Kvistad</surname><given-names>KA</given-names></name><name><surname>Haberg</surname><given-names>AK</given-names></name><name><surname>Salvesen</surname><given-names>O</given-names></name><name><surname>Berntsen</surname><given-names>EM</given-names></name></person-group><article-title>Growth dynamics of untreated glioblastomas in vivo</article-title><source>Neuro-Oncology</source><year>2015</year><volume>17</volume><fpage>1402</fpage><lpage>1411</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nov029</pub-id><?supplied-pmid 25758748?><pub-id pub-id-type="pmid">25758748</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellingson</surname><given-names>BM</given-names></name><name><surname>Nguyen</surname><given-names>HN</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Nechifor</surname><given-names>RE</given-names></name><name><surname>Zaw</surname><given-names>O</given-names></name><name><surname>Pope</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma</article-title><source>Cancer</source><year>2016</year><volume>122</volume><fpage>1718</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1002/cncr.29957</pub-id><?supplied-pmid 26998740?><pub-id pub-id-type="pmid">26998740</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stensjoen</surname><given-names>AL</given-names></name><name><surname>Berntsen</surname><given-names>EM</given-names></name><name><surname>Mikkelsen</surname><given-names>VE</given-names></name><name><surname>Torp</surname><given-names>SH</given-names></name><name><surname>Jakola</surname><given-names>AS</given-names></name><name><surname>Salvesen</surname><given-names>O</given-names></name><etal/></person-group><article-title>Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?</article-title><source>World Neurosurg</source><year>2017</year><volume>101</volume><fpage>686</fpage><lpage>94.e4</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2017.03.012</pub-id><?supplied-pmid 28300718?><pub-id pub-id-type="pmid">28300718</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikkelsen</surname><given-names>VE</given-names></name><name><surname>Stensjoen</surname><given-names>AL</given-names></name><name><surname>Berntsen</surname><given-names>EM</given-names></name><name><surname>Nordrum</surname><given-names>IS</given-names></name><name><surname>Salvesen</surname><given-names>O</given-names></name><name><surname>Solheim</surname><given-names>O</given-names></name><etal/></person-group><article-title>Histopathologic features in relation to pretreatment tumor growth in patients with glioblastoma</article-title><source>World Neurosurg</source><year>2018</year><volume>109</volume><fpage>e50</fpage><lpage>ee8</lpage><pub-id pub-id-type="doi">10.1016/j.wneu.2017.09.102</pub-id><?supplied-pmid 28951271?><pub-id pub-id-type="pmid">28951271</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>Y</given-names></name><name><surname>Durden</surname><given-names>DL</given-names></name><name><surname>Van Meir</surname><given-names>EG</given-names></name><name><surname>Brat</surname><given-names>DJ</given-names></name></person-group><article-title>'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>529</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1097/00005072-200606000-00001</pub-id><?supplied-pmid 16783163?><pub-id pub-id-type="pmid">16783163</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><?supplied-pmid 21376230?><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maxwell</surname><given-names>PH</given-names></name><name><surname>Dachs</surname><given-names>GU</given-names></name><name><surname>Gleadle</surname><given-names>JM</given-names></name><name><surname>Nicholls</surname><given-names>LG</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Stratford</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth</article-title><source>Proc Natl Acad Sci U S A</source><year>1997</year><volume>94</volume><fpage>8104</fpage><lpage>8109</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.15.8104</pub-id><?supplied-pmid 9223322?><pub-id pub-id-type="pmid">9223322</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blouw</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Tihan</surname><given-names>T</given-names></name><name><surname>Bosze</surname><given-names>J</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Gerber</surname><given-names>HP</given-names></name><etal/></person-group><article-title>The hypoxic response of tumors is dependent on their microenvironment</article-title><source>Cancer Cell</source><year>2003</year><volume>4</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00194-6</pub-id><?supplied-pmid 12957288?><pub-id pub-id-type="pmid">12957288</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>DL</given-names></name><name><surname>Whang</surname><given-names>K</given-names></name><name><surname>Ragel</surname><given-names>BT</given-names></name><name><surname>Flynn</surname><given-names>JR</given-names></name><name><surname>Kelly</surname><given-names>DA</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name></person-group><article-title>Silencing of hypoxia inducible factor-1alpha by RNA interference attenuates human glioma cell growth in vivo</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>2441</fpage><lpage>2448</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2692</pub-id><?supplied-pmid 17438103?><pub-id pub-id-type="pmid">17438103</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakariassen</surname><given-names>PO</given-names></name><name><surname>Prestegarden</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Skaftnesmo</surname><given-names>KO</given-names></name><name><surname>Mahesparan</surname><given-names>R</given-names></name><name><surname>Molthoff</surname><given-names>C</given-names></name><etal/></person-group><article-title>Angiogenesis-independent tumor growth mediated by stem-like cancer cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>16466</fpage><lpage>16471</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607668103</pub-id><?supplied-pmid 17056721?><pub-id pub-id-type="pmid">17056721</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinot</surname><given-names>OL</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Mason</surname><given-names>W</given-names></name><name><surname>Henriksson</surname><given-names>R</given-names></name><name><surname>Saran</surname><given-names>F</given-names></name><name><surname>Nishikawa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>709</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1308345</pub-id><?supplied-pmid 24552318?><pub-id pub-id-type="pmid">24552318</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilbert</surname><given-names>MR</given-names></name><name><surname>Dignam</surname><given-names>JJ</given-names></name><name><surname>Armstrong</surname><given-names>TS</given-names></name><name><surname>Wefel</surname><given-names>JS</given-names></name><name><surname>Blumenthal</surname><given-names>DT</given-names></name><name><surname>Vogelbaum</surname><given-names>MA</given-names></name><etal/></person-group><article-title>A randomized trial of bevacizumab for newly diagnosed glioblastoma</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>699</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1308573</pub-id><?supplied-pmid 24552317?><pub-id pub-id-type="pmid">24552317</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakocevic</surname><given-names>J</given-names></name><name><surname>Orlic</surname><given-names>D</given-names></name><name><surname>Mitrovic-Ajtic</surname><given-names>O</given-names></name><name><surname>Tomasevic</surname><given-names>M</given-names></name><name><surname>Dobric</surname><given-names>M</given-names></name><name><surname>Zlatic</surname><given-names>N</given-names></name><etal/></person-group><article-title>Endothelial cell markers from clinician's perspective</article-title><source>Exp Mol Pathol</source><year>2017</year><volume>102</volume><fpage>303</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.yexmp.2017.02.005</pub-id><?supplied-pmid 28192087?><pub-id pub-id-type="pmid">28192087</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hlatky</surname><given-names>L</given-names></name><name><surname>Hahnfeldt</surname><given-names>P</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us</article-title><source>J Natl Cancer Inst</source><year>2002</year><volume>94</volume><fpage>883</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1093/jnci/94.12.883</pub-id><?supplied-pmid 12072542?><pub-id pub-id-type="pmid">12072542</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nassiri</surname><given-names>F</given-names></name><name><surname>Cusimano</surname><given-names>MD</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Rotondo</surname><given-names>F</given-names></name><name><surname>Fazio</surname><given-names>A</given-names></name><name><surname>Yousef</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy</article-title><source>Anticancer Res</source><year>2011</year><volume>31</volume><fpage>2283</fpage><lpage>2290</lpage><?supplied-pmid 21737653?><pub-id pub-id-type="pmid">21737653</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Louis DN, Ohgaki H, Wiestler O, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. 4th ed. CH-1211 Geneva 27, Switzerland: International Agency for Research on Cancer (IARC); 2007.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Osborn AG. Astrocytomas. In: Renlund AR, editor. Osborn's brain: imaging, pathology and anatomy. First ed. Altona, Manitoba, Canada: Amirsys Publishing, Inc.; 2013. p. 484&#x02013;90.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>N</given-names></name><name><surname>Semple</surname><given-names>JP</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Folkman</surname><given-names>J</given-names></name></person-group><article-title>Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma</article-title><source>N Engl J Med</source><year>1991</year><volume>324</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199101033240101</pub-id><?supplied-pmid 1701519?><pub-id pub-id-type="pmid">1701519</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name></person-group><article-title>Molecular pathology of malignant gliomas</article-title><source>Annu Rev Pathol</source><year>2006</year><volume>1</volume><fpage>97</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.1.110304.100043</pub-id><?supplied-pmid 18039109?><pub-id pub-id-type="pmid">18039109</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraby</surname><given-names>MR</given-names></name><name><surname>Kruger</surname><given-names>K</given-names></name><name><surname>Opdahl</surname><given-names>S</given-names></name><name><surname>Vatten</surname><given-names>LJ</given-names></name><name><surname>Akslen</surname><given-names>LA</given-names></name><name><surname>Bofin</surname><given-names>AM</given-names></name></person-group><article-title>Microvascular proliferation in luminal a and basal-like breast cancer subtypes</article-title><source>J Clin Pathol</source><year>2015</year><volume>68</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2015-203037</pub-id><?supplied-pmid 26175265?><pub-id pub-id-type="pmid">26175265</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huszthy</surname><given-names>PC</given-names></name><name><surname>Daphu</surname><given-names>I</given-names></name><name><surname>Niclou</surname><given-names>SP</given-names></name><name><surname>Stieber</surname><given-names>D</given-names></name><name><surname>Nigro</surname><given-names>JM</given-names></name><name><surname>Sakariassen</surname><given-names>PO</given-names></name><etal/></person-group><article-title>In vivo models of primary brain tumors: pitfalls and perspectives</article-title><source>Neuro-Oncology</source><year>2012</year><volume>14</volume><fpage>979</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nos135</pub-id><?supplied-pmid 22679124?><pub-id pub-id-type="pmid">22679124</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tastekin</surname><given-names>E</given-names></name><name><surname>Caloglu</surname><given-names>VY</given-names></name><name><surname>Puyan</surname><given-names>FO</given-names></name><name><surname>Tokuc</surname><given-names>B</given-names></name><name><surname>Caloglu</surname><given-names>M</given-names></name><name><surname>Yalta</surname><given-names>TD</given-names></name><etal/></person-group><article-title>Prognostic value of angiogenesis and Survivin expression in patients with glioblastoma</article-title><source>Turk Neurosurg</source><year>2016</year><volume>26</volume><fpage>484</fpage><lpage>490</lpage><?supplied-pmid 27400093?><pub-id pub-id-type="pmid">27400093</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gillespie</surname><given-names>DL</given-names></name><name><surname>Stoddard</surname><given-names>GJ</given-names></name><name><surname>Reid</surname><given-names>JK</given-names></name><name><surname>Owens</surname><given-names>J</given-names></name><etal/></person-group><article-title>Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme</article-title><source>Cancer</source><year>2008</year><volume>113</volume><fpage>1032</fpage><lpage>1042</lpage><pub-id pub-id-type="doi">10.1002/cncr.23678</pub-id><?supplied-pmid 18618497?><pub-id pub-id-type="pmid">18618497</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name></person-group><article-title>Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody</article-title><source>Neuropathology</source><year>2005</year><volume>25</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1789.2005.00632.x</pub-id><?supplied-pmid 16193836?><pub-id pub-id-type="pmid">16193836</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behrem</surname><given-names>S</given-names></name><name><surname>Zarkovic</surname><given-names>K</given-names></name><name><surname>Eskinja</surname><given-names>N</given-names></name><name><surname>Jonjic</surname><given-names>N</given-names></name></person-group><article-title>Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma</article-title><source>Croat Med J</source><year>2005</year><volume>46</volume><fpage>417</fpage><lpage>422</lpage><?supplied-pmid 15861521?><pub-id pub-id-type="pmid">15861521</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>G</given-names></name><name><surname>Lama</surname><given-names>G</given-names></name><name><surname>Anile</surname><given-names>C</given-names></name><name><surname>Geloso</surname><given-names>MC</given-names></name><name><surname>La Torre</surname><given-names>G</given-names></name><name><surname>De Bonis</surname><given-names>P</given-names></name><etal/></person-group><article-title>Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma</article-title><source>Int J Oncol</source><year>2011</year><volume>38</volume><fpage>41</fpage><lpage>49</lpage><?supplied-pmid 21109924?><pub-id pub-id-type="pmid">21109924</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>SP</given-names></name><name><surname>Folkerth</surname><given-names>RD</given-names></name><name><surname>Black</surname><given-names>PM</given-names></name></person-group><article-title>Microvessel density is a prognostic indicator for patients with astroglial brain tumors</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19960115)77:2&#x0003c;362::AID-CNCR20&#x0003e;3.0.CO;2-Z</pub-id><?supplied-pmid 8625246?><pub-id pub-id-type="pmid">8625246</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Kong X, Wang Y, Liu S, Xing B, Yang Y, Li Y, et al. CD105 over-expression is associated with higher WHO grades for gliomas. Mol Neurobiol. 2016; 10.1007/s12035-015-9677-1.</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burrows</surname><given-names>FJ</given-names></name><name><surname>Derbyshire</surname><given-names>EJ</given-names></name><name><surname>Tazzari</surname><given-names>PL</given-names></name><name><surname>Amlot</surname><given-names>P</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name><name><surname>King</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy</article-title><source>Clin Cancer Res</source><year>1995</year><volume>1</volume><fpage>1623</fpage><lpage>1634</lpage><?supplied-pmid 9815965?><pub-id pub-id-type="pmid">9815965</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seon</surname><given-names>BK</given-names></name><name><surname>Matsuno</surname><given-names>F</given-names></name><name><surname>Haruta</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><name><surname>Barcos</surname><given-names>M</given-names></name></person-group><article-title>Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>1031</fpage><lpage>1044</lpage><?supplied-pmid 9815781?><pub-id pub-id-type="pmid">9815781</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>DW</given-names></name><name><surname>Graulich</surname><given-names>W</given-names></name><name><surname>Karges</surname><given-names>B</given-names></name><name><surname>Stahl</surname><given-names>S</given-names></name><name><surname>Ernst</surname><given-names>M</given-names></name><name><surname>Ramaswamy</surname><given-names>A</given-names></name><etal/></person-group><article-title>Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells</article-title><source>Int J Cancer</source><year>1999</year><volume>81</volume><fpage>568</fpage><lpage>572</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19990517)81:4&#x0003c;568::AID-IJC11&#x0003e;3.0.CO;2-X</pub-id><?supplied-pmid 10225446?><pub-id pub-id-type="pmid">10225446</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallas</surname><given-names>NA</given-names></name><name><surname>Samuel</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Gray</surname><given-names>MJ</given-names></name><name><surname>Lim</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Endoglin (CD105): a marker of tumor vasculature and potential target for therapy</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><fpage>1931</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4478</pub-id><?supplied-pmid 18381930?><pub-id pub-id-type="pmid">18381930</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Chadalavada</surname><given-names>K</given-names></name><name><surname>Wilshire</surname><given-names>J</given-names></name><name><surname>Kowalik</surname><given-names>U</given-names></name><name><surname>Hovinga</surname><given-names>KE</given-names></name><name><surname>Geber</surname><given-names>A</given-names></name><etal/></person-group><article-title>Glioblastoma stem-like cells give rise to tumour endothelium</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>829</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1038/nature09624</pub-id><?supplied-pmid 21102433?><pub-id pub-id-type="pmid">21102433</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krupinski</surname><given-names>J</given-names></name><name><surname>Kaluza</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name></person-group><article-title>Role of angiogenesis in patients with cerebral ischemic stroke</article-title><source>Stroke</source><year>1994</year><volume>25</volume><fpage>1794</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1161/01.STR.25.9.1794</pub-id><?supplied-pmid 7521076?><pub-id pub-id-type="pmid">7521076</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minhajat</surname><given-names>R</given-names></name><name><surname>Mori</surname><given-names>D</given-names></name><name><surname>Yamasaki</surname><given-names>F</given-names></name><name><surname>Sugita</surname><given-names>Y</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Tokunaga</surname><given-names>O</given-names></name></person-group><article-title>Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers</article-title><source>Pathol Int</source><year>2006</year><volume>56</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1827.2006.02037.x</pub-id><?supplied-pmid 17096728?><pub-id pub-id-type="pmid">17096728</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birner</surname><given-names>P</given-names></name><name><surname>Piribauer</surname><given-names>M</given-names></name><name><surname>Fischer</surname><given-names>I</given-names></name><name><surname>Gatterbauer</surname><given-names>B</given-names></name><name><surname>Marosi</surname><given-names>C</given-names></name><name><surname>Ambros</surname><given-names>PF</given-names></name><etal/></person-group><article-title>Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes</article-title><source>Brain Pathol</source><year>2003</year><volume>13</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2003.tb00013.x</pub-id><?supplied-pmid 12744467?><pub-id pub-id-type="pmid">12744467</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Pye</surname><given-names>D</given-names></name><name><surname>Haboubi</surname><given-names>N</given-names></name><name><surname>al-Nakib</surname><given-names>L</given-names></name></person-group><article-title>Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers</article-title><source>J Natl Cancer Inst</source><year>1994</year><volume>86</volume><fpage>386</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1093/jnci/86.5.386</pub-id><?supplied-pmid 7508519?><pub-id pub-id-type="pmid">7508519</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsubara</surname><given-names>S</given-names></name><name><surname>Bourdeau</surname><given-names>A</given-names></name><name><surname>terBrugge</surname><given-names>KG</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Letarte</surname><given-names>M</given-names></name></person-group><article-title>Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations</article-title><source>Stroke</source><year>2000</year><volume>31</volume><fpage>2653</fpage><lpage>2660</lpage><pub-id pub-id-type="doi">10.1161/01.STR.31.11.2653</pub-id><?supplied-pmid 11062290?><pub-id pub-id-type="pmid">11062290</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balza</surname><given-names>E</given-names></name><name><surname>Castellani</surname><given-names>P</given-names></name><name><surname>Zijlstra</surname><given-names>A</given-names></name><name><surname>Neri</surname><given-names>D</given-names></name><name><surname>Zardi</surname><given-names>L</given-names></name><name><surname>Siri</surname><given-names>A</given-names></name></person-group><article-title>Lack of specificity of endoglin expression for tumor blood vessels</article-title><source>Int J Cancer</source><year>2001</year><volume>94</volume><fpage>579</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1002/ijc.1505</pub-id><?supplied-pmid 11745447?><pub-id pub-id-type="pmid">11745447</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardee</surname><given-names>ME</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name></person-group><article-title>Mechanisms of glioma-associated neovascularization</article-title><source>Am J Pathol</source><year>2012</year><volume>181</volume><fpage>1126</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.06.030</pub-id><?supplied-pmid 22858156?><pub-id pub-id-type="pmid">22858156</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holash</surname><given-names>J</given-names></name><name><surname>Maisonpierre</surname><given-names>PC</given-names></name><name><surname>Compton</surname><given-names>D</given-names></name><name><surname>Boland</surname><given-names>P</given-names></name><name><surname>Alexander</surname><given-names>CR</given-names></name><name><surname>Zagzag</surname><given-names>D</given-names></name><etal/></person-group><article-title>Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF</article-title><source>Science</source><year>1999</year><volume>284</volume><fpage>1994</fpage><lpage>1998</lpage><pub-id pub-id-type="doi">10.1126/science.284.5422.1994</pub-id><?supplied-pmid 10373119?><pub-id pub-id-type="pmid">10373119</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyden</surname><given-names>D</given-names></name><name><surname>Hattori</surname><given-names>K</given-names></name><name><surname>Dias</surname><given-names>S</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Blaikie</surname><given-names>P</given-names></name><name><surname>Butros</surname><given-names>L</given-names></name><etal/></person-group><article-title>Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth</article-title><source>Nat Med</source><year>2001</year><volume>7</volume><fpage>1194</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1038/nm1101-1194</pub-id><?supplied-pmid 11689883?><pub-id pub-id-type="pmid">11689883</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepper</surname><given-names>MS</given-names></name></person-group><article-title>Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity</article-title><source>Cytokine Growth Factor Rev</source><year>1997</year><volume>8</volume><fpage>21</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/S1359-6101(96)00048-2</pub-id><?supplied-pmid 9174661?><pub-id pub-id-type="pmid">9174661</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Zhang</surname><given-names>QP</given-names></name><name><surname>Mu</surname><given-names>YG</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Sai</surname><given-names>K</given-names></name><name><surname>Pang</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Clinical significance of vasculogenic mimicry in human gliomas</article-title><source>J Neuro-Oncol</source><year>2011</year><volume>105</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1007/s11060-011-0578-5</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><etal/></person-group><article-title>Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>41947</fpage><lpage>41962</lpage><?supplied-pmid 28410212?><pub-id pub-id-type="pmid">28410212</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Rahimpour</surname><given-names>S</given-names></name><name><surname>Nesvick</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>11882</fpage><lpage>11893</lpage><?supplied-pmid 25957416?><pub-id pub-id-type="pmid">25957416</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>JF</given-names></name><name><surname>Fuller</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>AJ</given-names></name><name><surname>Piao</surname><given-names>Y</given-names></name><name><surname>Eterovic</surname><given-names>K</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice</article-title><source>Neuro-Oncology</source><year>2010</year><volume>12</volume><fpage>233</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nop027</pub-id><?supplied-pmid 20167811?><pub-id pub-id-type="pmid">20167811</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, et al. Radiologic progression of glioblastoma under therapy - an exploratory analysis of AVAglio. Neuro-Oncology. 2017; 10.1093/neuonc/nox162.</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Obad N, Espedal H, Jirik R, Sakariassen PO, Brekke Rygh C, Lund-Johansen M, et al. Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma. J Cereb Blood Flow Metab. 2017:271678x17714656. 10.1177/0271678x17714656.</mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keunen</surname><given-names>O</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Oudin</surname><given-names>A</given-names></name><name><surname>Sanzey</surname><given-names>M</given-names></name><name><surname>Rahim</surname><given-names>SA</given-names></name><name><surname>Fack</surname><given-names>F</given-names></name><etal/></person-group><article-title>Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>3749</fpage><lpage>3754</lpage><pub-id pub-id-type="doi">10.1073/pnas.1014480108</pub-id><?supplied-pmid 21321221?><pub-id pub-id-type="pmid">21321221</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scribner</surname><given-names>E</given-names></name><name><surname>Saut</surname><given-names>O</given-names></name><name><surname>Province</surname><given-names>P</given-names></name><name><surname>Bag</surname><given-names>A</given-names></name><name><surname>Colin</surname><given-names>T</given-names></name><name><surname>Fathallah-Shaykh</surname><given-names>HM</given-names></name></person-group><article-title>Effects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e115018</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0115018</pub-id><?supplied-pmid 25506702?><pub-id pub-id-type="pmid">25506702</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giese</surname><given-names>A</given-names></name><name><surname>Loo</surname><given-names>MA</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Haskett</surname><given-names>D</given-names></name><name><surname>Coons</surname><given-names>SW</given-names></name><name><surname>Berens</surname><given-names>ME</given-names></name></person-group><article-title>Dichotomy of astrocytoma migration and proliferation</article-title><source>Int J Cancer</source><year>1996</year><volume>67</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19960717)67:2&#x0003c;275::AID-IJC20&#x0003e;3.0.CO;2-9</pub-id><?supplied-pmid 8760599?><pub-id pub-id-type="pmid">8760599</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzikirou</surname><given-names>H</given-names></name><name><surname>Basanta</surname><given-names>D</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Schaller</surname><given-names>K</given-names></name><name><surname>Deutsch</surname><given-names>A</given-names></name></person-group><article-title>&#x02018;Go or grow&#x02019;: the key to the emergence of invasion in tumour progression?</article-title><source>Math Med Biol</source><year>2012</year><volume>29</volume><fpage>49</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1093/imammb/dqq011</pub-id><?supplied-pmid 20610469?><pub-id pub-id-type="pmid">20610469</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname><given-names>M</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name><name><surname>Kurozumi</surname><given-names>K</given-names></name><name><surname>Date</surname><given-names>I</given-names></name></person-group><article-title>Angiogenesis and invasion in glioma</article-title><source>Brain Tumor Pathol</source><year>2011</year><volume>28</volume><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s10014-010-0007-z</pub-id><?supplied-pmid 21221826?><pub-id pub-id-type="pmid">21221826</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prayson</surname><given-names>RA</given-names></name></person-group><article-title>Cell proliferation and tumors of the central nervous system. Part 1: evaluation of mitotic activity</article-title><source>J Neuropathol Exp Neurol</source><year>2002</year><volume>61</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1093/jnen/61.6.501</pub-id><?supplied-pmid 12071633?><pub-id pub-id-type="pmid">12071633</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeulen</surname><given-names>PB</given-names></name><name><surname>Gasparini</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>SB</given-names></name><name><surname>Colpaert</surname><given-names>C</given-names></name><name><surname>Marson</surname><given-names>LP</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><etal/></person-group><article-title>Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours</article-title><source>Eur J Cancer</source><year>2002</year><volume>38</volume><fpage>1564</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(02)00094-1</pub-id><?supplied-pmid 12142044?><pub-id pub-id-type="pmid">12142044</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M</given-names></name><name><surname>Heinzl</surname><given-names>H</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Schonegger</surname><given-names>K</given-names></name><name><surname>Haberler</surname><given-names>C</given-names></name><name><surname>Birner</surname><given-names>P</given-names></name><etal/></person-group><article-title>Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: poor observer agreement limits clinical utility as prognostic factors: a translational research project of the European Organization for Research and Treatment of Cancer brain tumor group</article-title><source>Cancer</source><year>2006</year><volume>107</volume><fpage>162</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1002/cncr.21973</pub-id><?supplied-pmid 16721804?><pub-id pub-id-type="pmid">16721804</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>PJ</given-names></name><name><surname>Daumas-Duport</surname><given-names>C</given-names></name><name><surname>Kispert</surname><given-names>DB</given-names></name><name><surname>Kall</surname><given-names>BA</given-names></name><name><surname>Scheithauer</surname><given-names>BW</given-names></name><name><surname>Illig</surname><given-names>JJ</given-names></name></person-group><article-title>Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms</article-title><source>J Neurosurg</source><year>1987</year><volume>66</volume><fpage>865</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.3171/jns.1987.66.6.0865</pub-id><?supplied-pmid 3033172?><pub-id pub-id-type="pmid">3033172</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamahara</surname><given-names>T</given-names></name><name><surname>Numa</surname><given-names>Y</given-names></name><name><surname>Oishi</surname><given-names>T</given-names></name><name><surname>Kawaguchi</surname><given-names>T</given-names></name><name><surname>Seno</surname><given-names>T</given-names></name><name><surname>Asai</surname><given-names>A</given-names></name><etal/></person-group><article-title>Morphological and flow cytometric analysis of cell infiltration in glioblastoma: a comparison of autopsy brain and neuroimaging</article-title><source>Brain Tumor Pathol.</source><year>2010</year><volume>27</volume><fpage>81</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/s10014-010-0275-7</pub-id><?supplied-pmid 21046309?><pub-id pub-id-type="pmid">21046309</pub-id></element-citation></ref></ref-list></back></article>